Latest Health News

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.

SportsHero Limited has arranged a $1 million unsecured loan facility to support its working capital needs, with flexible monthly drawdowns and a fixed 10% interest rate. The company has already drawn $100,000 from this facility, signaling ongoing liquidity management efforts.

Regional Express Holdings has completed the transfer of debt from PAGAC Regulus Holding to the Commonwealth of Australia, marking a key step in its ongoing administration process.

Australian Rare Earths Limited has secured a $5 million government grant to advance its Koppamurra Rare Earths Project, while initial drilling at its Overland Uranium Project validates promising geological models for uranium deposits.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.

Gryphon Capital Income Trust has announced an estimated ordinary dividend of AUD 0.0141 per unit for January 2025, payable in February. The distribution is unfranked and reflects the trust's ongoing income strategy.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Forbidden Foods Limited has more than doubled its group revenues in Q2 FY25 following the acquisition of Oat Milk Goodness, driven by expanded retail distribution and strong ecommerce growth.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

Mandrake Resources has announced a significant maiden Inferred Resource of 3.3 million tonnes of Lithium Carbonate Equivalent at its Utah Lithium Project, alongside securing a US$1 million grant from the US Department of Energy to support further exploration and development.